Replies to post #124387 on Biotech Values

[vinmantoo]

Thanks Dew. I was always concerned at the operating margins with DNDN since each vaccine is custom made, so the cost would be high and profit low. When you factor in what BSR_David wrote about DNDN eating the expense it shipping delays destroy Provenge, or patients stopping treatment after the first does, it does make one wonder how the analysts could come up with the high sales projections and rapid sales escalation that they did.

You made a comment that you thought that DNDN would end up around $20. That price would still place its market cap at $3 billion.